Abstract Background and Aims Some patients with ulcerative colitis [UC] do not respond to
vedolizumab treatment despite adequate drug exposure in serum. This study aimed to …

BACKGROUND & AIMS Patients with ulcerative colitis (UC) may experience nonresponse to
biologics, possibly due to low drug exposure. This trial assessed the efficacy of dose …

Background The association between vedolizumab (VDZ) exposure and treatment response
is unclear and seems insufficiently explained by serum levels. The aim of this study was to …

Background Vedolizumab inhibits α4β7-mediated lymphocyte trafficking and is effective in
ulcerative colitis (UC). This study evaluated drug and biomarker concentrations and patient …

Abstract Background and Aims This GEMINI 1 post hoc analysis evaluated vedolizumab
efficacy for inducing deep remission in patients with ulcerative colitis and correlation …

Randomized controlled clinical trials and real-life observations indicate that less than 50% of
patients with Crohn's disease (CD) or ulcerative colitis (UC) respond to vedolizumab, a …

Background & Aims We created and validated a clinical decision support tool (CDST) to
predict outcomes of vedolizumab therapy for ulcerative colitis (UC). Methods We performed …

Background Sustaining clinical remission is an important treatment goal in moderate-to-
severe UC. This post hoc exploratory analysis assessed the long-term efficacy of …

Abstract Background and Aim Vedolizumab is a humanized monoclonal antibody that
selectively inhibits the migration of gut‐homing memory T cells into the intestinal submucosa …

Background: Vedolizumab was approved for the therapy of ulcerative colitis and Crohn's
disease in mid-2014. Real-world treatment data are necessary for a balanced assessment of …